Infectious Disease

Fisher SS, Lindaas A, Muthuri SG, Lloyd PC, Gruber JF, Richey MM, Lyu H, Cheng AS, Kowarski LS, McKillop MM, Bui C, Clarke TC, Beers J, Burrell T, Duenas PF, Chen Y, Sheng M, Forshee RA, Anderson SA, Chillarige Y, Anthony MS, Shoaibi A, Layton JB. Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States. PLoS One. 2025 Nov 24;20(11):e0333704. doi: 10.1371/journal.pone.0333704


Wilson MR, Pullagura GR, Weicker S, Warren S. Cost-effectiveness analysis of pediatric and adult pneumococcal conjugate vaccine strategies in Canada. Poster presented at the ISPOR Europe 2025; November 9, 2025. Glasgow, Scotland.


Herrera-Restrepo O, Shah H, Jutlla G, Graham J, Grace M, Carrico J, Kocaata Z, Poston S, Clements D, Andani A, Burman C. Public health impact and cost-effectiveness of vaccination strategies against invasive meningococcal disease in adolescents in the United States. Poster presented at the ID Week 2025; October 21, 2025. Atlanta, GA.


Abstract not available at this time.

Mugwagwa T, Marcano Belisario J, Hartley L, Phan NTN. Nirmatrelvir/ritonavir treatment for COVID-19: an economic value systematic literature review. J Med Econ. 2025 Nov 6;28(1):1933-54. doi: 10.1080/13696998.2025.2579407


Hitchens A, Candrilli SD, Carrico J, Hicks KA, Wilson E, Mehta D, Panozzo CA, Ghaswalla P. Prevalence of health conditions associated with higher risk for severe respiratory syncytial virus, influenza, or COVID-19. Curr Med Res Opin. 2025 Jul 30;41(7):1353-61. doi: 10.1080/03007995.2025.2535456


Blick G, Santiago-Colon L, Richardson D, Sherif B, Zografos L, Schubert C, Merrill D, Teichner P, Garris C. Clinical outcomes at month 24 after initiation of cabotegravir and rilpivirine long acting (CAB+RPV LA) in an observational real-world study (BEYOND). Poster presented at the International AIDS Society (IAS) 2025 Conference; July 17, 2025. Kigali, Rwanda.


BACKGROUND: CAB+RPV LA is the first complete long-acting regimen for virologically suppressed people with HIV (PWH). The BEYOND real-world study describes the clinical outcomes of PWH initiating CAB+RPV LA in the US.

Felizarta F, Alozie O, Miller R, Nelson K, Reynolds M, Richardson D, Nguyen K, Teichner P, Garris C. Perspectives of people living with HIV (PWH) 24 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND). Poster presented at the International AIDS Society (IAS) 2025 Conference; July 17, 2025. Kigali, Rwanda.


BACKGROUND: CAB+RPV LA is the only complete long-acting regimen administered by a healthcare provider for treatment of virologically suppressed PWH. CAB+RPV LA may alleviate challenges associated with daily oral antiretroviral therapy (ART). This study reports perspectives of PWH receiving CAB+RPV LA in real-world US healthcare settings.

Yeung MW, Tuite A, Nam A, Ximenes R, Arthurs E, Awan A, Khaliq S, Loukov D, Carrico J, Hicks K. Cost-effectiveness analyses for SHINGRIX (RZV) in 18+ IC populations in Canada. Presented at National Advisory Committee on Immunization Herpes Zoster Working Group; November 1, 2021. Virtual.


Abstract not available at this time.

Ghaswalla P, Joshi K, Hicks K, Xiao Z, Fust K, Kohli M, Weinstein MC. Preliminary cost-effectiveness of Moderna's RSV vaccine, mRNA-1345 (mRESVIA) compared to no vaccination in adults 50-59 years at increased risk of severe RSV disease in the United States. Presented at US Advisory Committee on Immunization Practices Respiratory Syncytial Virus Vaccines – Adult Work Group; January 24, 2025. Atlanta, GA.


Abstract not available at this time.

Herrera-Restrepo O, Shah H, Kocaata Z, Poston S, Graham J, Hicks KA, Carrico J, Grace M. Cost-effectiveness analysis of a pentavalent (MenABCWY) vaccine for vaccinating adolescents and young adults against invasive meningococcal disease in the United States. Presented at the US Advisory Committee on Immunization Practices Meningococcal Vaccines Work Group; September 12, 2024. Atlanta, GA.


Abstract not available at this time.

Subscribe to Infectious Disease